Article
Multidisciplinary Sciences
Xu Zhao, Jizhao Wang, Rui Zhu, Jing Zhang, Yunfeng Zhang
Summary: DLX6-AS1 regulates cisplatin sensitivity of lung squamous cell carcinoma cells through the miR-181a-5p/miR-382-5p/CELF1 axis, playing a key role in promoting secondary cisplatin resistance. Targeting DLX6-AS1 may be a novel approach to overcome cisplatin resistance in lung squamous cell carcinoma.
SCIENTIFIC REPORTS
(2021)
Article
Medicine, Research & Experimental
Tae Won Kim, Haein Ji, Nak Hyeon Yun, Chang Hoon Shin, Hyeon Ho Kim, Yong Beom Cho
Summary: This study identified AFAP1-AS1 and MLK7-AS1 as ceRNAs that promote the progression of colorectal cancer by reducing the levels of tumor-suppressing miRNAs miR-149-5p and miR-485-5p.
MOLECULAR THERAPY-NUCLEIC ACIDS
(2023)
Article
Biochemistry & Molecular Biology
Zhiping Chen, Tianyu Zhong, Tao Li, Jinghua Zhong, Yang Tang, Zhanyu Liu, Baodian Ling, Lanfeng Wang
Summary: The study revealed that SNHG15 exerts oncogenic properties in gastric cancer by targeting miR-506-5p, potentially offering a novel target for GC treatment.
BIOSCIENCE REPORTS
(2021)
Article
Oncology
Zhongling Ma, Gang Liu, Suhong Hao, Tianfu Zhao, Wei Chang, Jiansheng Wang, Hong Ren, Xinhan Zhao
Summary: This study found that the overexpression of lncRNA PITPNA-AS1 in gastric cancer is associated with poor survival. Inhibiting PITPNA-AS1 can inhibit cell growth and induce apoptotic cell death in gastric cancer cells. Furthermore, PITPNA-AS1 is elevated in cisplatin-resistant gastric cancer cells, and its inhibition can increase the sensitivity of gastric cancer cells to cisplatin treatment.
JOURNAL OF ONCOLOGY
(2022)
Article
Oncology
Gang Wang, Fangzheng Zhou, Tong Ou, Haiyan Sun, Zhirui Shan, Yingshen Lu, Gui Chen, Simin Yuan, Xiaowen Zhang, Song Wu
Summary: The dysregulation of miR-182-5p has been identified as potential diagnostic and prognostic biomarkers for some cancers, however, its role in nasopharyngeal carcinoma (NPC) had not been explored. Our study demonstrated that up-regulation of miR-182-5p in NPC is associated with tumor development and poor prognosis, and it facilitates cell proliferation and migration by down-regulating ZFP36L1 expression through a HIF-1 alpha/miR-182-5p/ZFP36L1 axis, suggesting a novel therapeutic target for NPC management.
CANCER CELL INTERNATIONAL
(2021)
Article
Oncology
TianWei Guo, Wei Wang, YueXia Ji, Min Zhang, GuoYing Xu, Sen Lin
Summary: The study revealed that PROX1-AS1 plays a role in gastric cancer progression through the miR-877-5p/PD-L1 axis, suggesting it may serve as a new therapeutic target for the diagnosis and treatment of GC patients.
CANCER MANAGEMENT AND RESEARCH
(2021)
Article
Oncology
Xiaobin Liao, Linbao Wen, Liqiong Luo
Summary: The increased expression of NR2F1-AS1 and MAP3K2 in gastric cancer tissues and cells was found to significantly suppress cell proliferation and migration, while enhancing cell apoptosis. Additionally, NR2F1-AS1 was identified as a sponge of miR-493-5p, upregulating MAP3K2 expression.
JOURNAL OF ONCOLOGY
(2021)
Article
Gastroenterology & Hepatology
Haixiao Wang, Guangli Sun, Penghui Xu, Jialun Lv, Xing Zhang, Lu Zhang, Sen Wang, Jiacheng Cao, Yiwen Xia, Zhe Xuan, Bowen Li, Xiaoxu Huang, Tianlu Jiang, Lang Fang, Zekuan Xu
Summary: Our study revealed that circTMEM87A is upregulated in GC tissues and cell lines, and its high expression is associated with poor prognosis in GC patients. CircTMEM87A functions as an oncogene by sponging miR-142-5p to regulate ULK1 expression and promote GC progression, indicating its potential as a prognostic biomarker and therapeutic target in GC.
JOURNAL OF GASTROENTEROLOGY
(2021)
Article
Biochemistry & Molecular Biology
Haijun Mei, Hua Xian, Jing Ke
Summary: The study revealed that LncRNA-MCM3AP-AS1 promotes the progression of infantile hemangiomas by increasing glycolysis through regulating miR-106b-3p and HIF-1 alpha, contributing to understanding the pathogenesis of the disease.
FRONTIERS IN MOLECULAR BIOSCIENCES
(2021)
Article
Oncology
Qing Li, Dachuan Zhang, Hui Wang, Jun Xie, Lei Peng, Yan Peng, Xiao Zheng, Jingting Jiang
Summary: The overexpression of SLCO4A1-AS1 in gastric cancer promotes cell proliferation, migration, and invasion, inhibits apoptosis, and may mediate these effects through miR-149-5p and STAT3. miR-149-5p mimic can suppress the malignant development of gastric cancer cells.
JOURNAL OF ONCOLOGY
(2021)
Article
Medicine, General & Internal
Duanyang Zhai, Yu Zhou, Xiaying Kuang, Fangyuan Shao, Tiantian Zhen, Ying Lin, Qing Wang, Nan Shao
Summary: This study identified a novel lnc NR2F1-AS1/miR-25-3p/ZEB2 axis in breast cancer metastasis, suggesting that lnc NR2F1-AS1 could be a potential therapeutic target for breast cancer metastasis.
INTERNATIONAL JOURNAL OF MEDICAL SCIENCES
(2023)
Article
Biochemistry & Molecular Biology
Xiao-Yu Zhang, Hai-Wen Zhuang, Jian Wang, Yu Shen, Yan-Zhi Bu, Bu-Gao Guan, Fang Xu, Jin Dou
Summary: This study found that CA3-AS1 functions as a tumor suppressor in gastric cancer by inhibiting cell migration and invasion, and it affects the expression of gastric cancer cells through its interaction with miR-93-5p. This discovery has important implications for the clinical treatment of gastric cancer.
Article
Oncology
Xinping Chen, Weihua Xu, Zhichao Ma, Juan Zhu, Junjie Hu, Xiaojuan Li, Shengmiao Fu
Summary: This study focused on the involvement of TTN-AS1 in nasopharyngeal carcinoma (NPC) and its impact on the progression of NPC. The results showed that TTN-AS1 was highly expressed in NPC cells and its depletion inhibited cell proliferation, migration, and invasion while stimulating apoptosis. TTN-AS1 was found to interact with miR-876-5p and UPF1, enhancing the expression of NETO2. Additionally, TTN-AS1 could be transcriptionally activated by YY1 in NPC cells. These findings provide valuable insights into the development of effective treatments for NPC.
MOLECULAR THERAPY-ONCOLYTICS
(2022)
Article
Biotechnology & Applied Microbiology
Peng Du, Kaifeng Luo, Guoyong Li, Jisheng Zhu, Qi Xiao, Yong Li, Xingjian Zhang
Summary: The study revealed that VCAN-AS1 is upregulated in breast cancer and promotes its progression by regulating the miR-106a-5p-mediated STAT3/HIF-1 alpha pathway, providing a new target for BC therapy.
Article
Medicine, Research & Experimental
Minzhen Qin, Yiliang Meng, Chunying Luo, Shougao He, Fengxue Qin, Yixia Yin, Junling Huang, Hailiang Zhao, Jing Hu, Zhihua Deng, Yiying Qiu, Gaoyu Hu, Hanhe Pan, Zongshuai Qin, Zansong Huang, Tingzhuang Yi
Summary: PRR34-AS1 is highly expressed in HCC and promotes cell proliferation, migration, and invasion by modulating the Wnt/β-catenin pathway. It sequesters miR-296-5p to positively regulate E2F2 and SOX12 in HCC. These findings suggest that PRR34-AS1 may serve as a potential therapeutic target for HCC.
MOLECULAR THERAPY-NUCLEIC ACIDS
(2021)